Plain-English translation of NCT07361029 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing LentiGen® CD19 Chimeric Antigen Receptor (CAR) T Cells, a personalized immune cell therapy designed to fight acute lymphoblastic leukemia (ALL) that has come back or stopped responding to chemotherapy. Researchers will give patients increasing doses of these specially engineered cells to find the safest and most effective dose. The treatment works by taking your own immune cells, modifying them in the lab to recognize and attack leukemia cells, and then infusing them back into your body.
ALL is an aggressive blood cancer that can return even after initial treatment, and some patients develop resistance to standard chemotherapy. This medication is being tested because early research suggests that training immune cells to specifically target leukemia cells may help patients whose cancer has become difficult to treat.
You likely qualify if…
You likely don't qualify if…
You will receive a single infusion of the modified immune cells through an IV. Because this is a dose-escalation study, the first participant in each dose group will be monitored for at least 4 weeks before the next participant receives treatment, and subsequent participants are spaced 2 weeks apart to ensure safety. You will need to attend follow-up visits to have blood tests and assessments to monitor how well the treatment is working and watch for any side effects. The study will track your response to treatment over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Saudi Arabia